HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<p>After more than 20 years of development in China, independent clinical laboratory (ICL) has achieved rapid growth, especially during the COVID-19. After <a href="https://www.smartkarma.com/entities/guangzhou-kingmed-diagnostics" target="_blank" data-smartkarma-citation="entities:30257:1" rel="noopener">Guangzhou Kingmed Diagnostics (603882 CH)</a> and <a href="https://www.smartkarma.com/entities/zhejiang-dian-diagnostics-a" target="_blank" data-smartkarma-citation="entities:19115:1" rel="noopener">Zhejiang Dian Diagnostics A (300244 CH) </a>got listed, the third-ranking ICL service provider in China, <a href="https://www.smartkarma.com/entities/adicon-holdings-limited" target="_blank" data-smartkarma-citation="entities:33786:1" rel="noopener">ADICON Holdings Limited (ADI HK)</a>, is also preparing to go public. On June 30, 2021, ADICON submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the business, and the concerns of the Company.</p>

After more than 20 years of development in China, independent clinical laboratory (ICL) has achieved rapid growth, especially during the COVID-19. After Guangzhou Kingmed Diagnostics (603882 CH) and Zhejiang Dian Diagnostics A (300244 CH) got listed, the third-ranking ICL service provider in China, ADICON Holdings Limited (ADI HK), is also preparing to go public. On June 30, 2021, ADICON submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the business, and the concerns of the Company.

Pre-IPO ADICON Holdings Ltd - Insights on Industry, Business and Concerns

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Kindstar Globalgene Technology / Equity Capital Markets

<div><p><a href="https://www.smartkarma.com/entities/kindstar-globalgene-technology-inc" target="_blank" data-smartkarma-citation="entities:32175:1" rel="noopener">Kindstar Globalgene Technology (9960 HK)</a> is a leading independent esoteric clinical testing service provider in China. Kindstar provides full-spectrum testing services primarily to hospitals in various speciality areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. In 2020, Kindstar had a 4.1% revenue market share of the total esoteric testing market in China, according to Frost &amp; Sullivan. </p></div><div><p>At the proposed IPO price range of HK$8.60-9.78 per share, Kindstar will have a market cap of HK$7,788.3-8,857.0 ($1.0-1.1 billion). At the mid-point of the IPO price range, the total net proceeds are HK$1,931.1 million ($250 million). </p></div><div><p>Seven cornerstone investors will subscribe for $140 million of the offer shares (52.2% of the offer shares at the mid-point of the IPO price). The cornerstone investors include BlackRock, CPE, Snow Lake Capital, Carmignac Funds, Natixis Investment Managers, Athos Capital and IvyRock Asset Management.</p></div><div><div><div class="content-highlight"><p>In <a href="https://www.smartkarma.com/insights/kindstar-globalgene-ipo-initiation-testing-testing" target="_blank" data-smartkarma-citation="insights:53731" rel="noopener">Kindstar Globalgene IPO Initiation: Testing, Testing</a>, we stated that the business has successfully overcome the negative impact of the COVID-19 pandemic, with most of its segments displaying either a return to growth or lower revenue declines in 4Q20 in comparison to 9M20. In combination, with solid operating leverage and cash generation, we think that the Kindstar IPO is worth a look. Overall, we would participate in the IPO due to an attractive IPO price range.</p></div></div></div>

Kindstar Globalgene Technology (9960 HK) is a leading independent esoteric clinical testing service provider in China. Kindstar provides full-spectrum testing services primarily to hospitals in various speciality areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. In 2020, Kindstar had a 4.1% revenue market share of the total esoteric testing market in China, according to Frost &amp; Sullivan. At the proposed IPO price range of HK$8.60-9.78 per share, Kindstar will have a market cap of HK$7,788.3-8,857.0 ($1.0-1.1 billion). At the mid-point of the IPO price range, the total net proceeds are HK$1,931.1 million ($250 million). Seven cornerstone investors will subscribe for $140 million of the offer shares (52.2% of the offer shares at the mid-point of the IPO price). The cornerstone investors include BlackRock, CPE, Snow Lake Capital, Carmignac Funds, Natixis Investment Managers, Athos Capital and IvyRock Asset Management.In Kindstar Globalgene IPO Initiation: Testing, Testing, we stated that the business has successfully overcome the negative impact of the COVID-19 pandemic, with most of its segments displaying either a return to growth or lower revenue declines in 4Q20 in comparison to 9M20. In combination, with solid operating leverage and cash generation, we think that the Kindstar IPO is worth a look. Overall, we would participate in the IPO due to an attractive IPO price range.

Kindstar Globalgene IPO: Valuation Insights

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

<p>Kindstar is a leading esoteric test service provider in China. The company launched book building to raise up to USD 285m via a Hong Kong listing.</p><p>In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma-related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent. We also compared the company's key financial metrics with other leading listed ICL.</p><p>In this note, we provide an update for the book building. We think the company's fairly valued for its fundamentals.</p>

Kindstar is a leading esoteric test service provider in China. The company launched book building to raise up to USD 285m via a Hong Kong listing.In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma-related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent. We also compared the company's key financial metrics with other leading listed ICL.In this note, we provide an update for the book building. We think the company's fairly valued for its fundamentals.

Kindstar Globalgene (康圣环球) IPO: Fairly Valued for a Questionable Moat

<p><a href="https://www.smartkarma.com/entities/kindstar-globalgene-technology-inc" target="_blank" data-smartkarma-citation="entities:32175:1" rel="noopener">Kindstar Globalgene Technology (1868874D HK)</a> is a leading independent esoteric clinical testing service provider in China. Kindstar provides full-spectrum testing services primarily to hospitals in various speciality areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. In 2020, Kindstar had a 4.1% revenue market share of the total esoteric testing market in China, according to Frost &amp; Sullivan. </p><p>Kindstar is set to launch an HKEx IPO to raise around $300 million, according to press reports. Kindstar’s shareholders include Morningside, Investcorp, KPCB, Mayo Clinic and CPE.</p><p>ICLs (independent clinical laboratory) such as Kindstar provide hospitals with a wide range of testing services that they are not capable of conducting in-house. China’s ICL market consists of routine and esoteric testing. The size of China’s esoteric testing market is forecasted to increase from RMB20,057.6 million in 2020 to RMB27,860.1 million in 2025, representing a CAGR of 6.8% from 2020 to 2025, according to Frost &amp; Sullivan. </p><div class="content-highlight"><p>Kindstar is well-paced to benefit from this market opportunity as it has the largest esoteric testing portfolio among all the independent esoteric testing providers in China. The business has successfully overcome the negative impact of the COVID-19 pandemic, with most of its segments displaying either a return to growth or lower revenue declines in 4Q20 in comparison to 9M20. In combination, with solid operating leverage and cash generation, we think that the Kindstar IPO is worth a look. </p></div>

Kindstar Globalgene Technology (1868874D HK) is a leading independent esoteric clinical testing service provider in China. Kindstar provides full-spectrum testing services primarily to hospitals in various speciality areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases. In 2020, Kindstar had a 4.1% revenue market share of the total esoteric testing market in China, according to Frost &amp; Sullivan. Kindstar is set to launch an HKEx IPO to raise around $300 million, according to press reports. Kindstar’s shareholders include Morningside, Investcorp, KPCB, Mayo Clinic and CPE.ICLs (independent clinical laboratory) such as Kindstar provide hospitals with a wide range of testing services that they are not capable of conducting in-house. China’s ICL market consists of routine and esoteric testing. The size of China’s esoteric testing market is forecasted to increase from RMB20,057.6 million in 2020 to RMB27,860.1 million in 2025, representing a CAGR of 6.8% from 2020 to 2025, according to Frost &amp; Sullivan. Kindstar is well-paced to benefit from this market opportunity as it has the largest esoteric testing portfolio among all the independent esoteric testing providers in China. The business has successfully overcome the negative impact of the COVID-19 pandemic, with most of its segments displaying either a return to growth or lower revenue declines in 4Q20 in comparison to 9M20. In combination, with solid operating leverage and cash generation, we think that the Kindstar IPO is worth a look. 

Kindstar Globalgene IPO Initiation: Testing, Testing

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Index Rebalance

<p>Post market close on 28 May, the China Securities Index Company announced the changes to the <a href="https://www.smartkarma.com/entities/shanghai-shenzhen-csi-300-index" target="_blank" data-smartkarma-citation="entities:22906:1" rel="noopener">Shanghai Shenzhen CSI 300 Index (SHSZ300 INDEX)</a> that will be effective after the close of trading on 11 June.</p><p>There are 25 inclusions and exclusions in the review with an estimated one-way turnover of 3.67%.</p><p>There are 10 trading days to implementation of the changes. There are 4 inclusions that will have over 1 day of ADV to buy from passive funds while there are 15 deletions that will have over 1 day of ADV to sell. The actual impact could be higher as cash and carry baskets are rebalanced and active managers reposition their portfolios to no deviate too far from their benchmark.</p><p>The inclusions have outperformed the deletions by 15% over the last month and while there could be a pop in the returns over the next few sessions, we recommend gradually exiting existing positions and re-entering prior to implementation on a selloff in the trade.</p>

Post market close on 28 May, the China Securities Index Company announced the changes to the Shanghai Shenzhen CSI 300 Index (SHSZ300 INDEX) that will be effective after the close of trading on 11 June.There are 25 inclusions and exclusions in the review with an estimated one-way turnover of 3.67%.There are 10 trading days to implementation of the changes. There are 4 inclusions that will have over 1 day of ADV to buy from passive funds while there are 15 deletions that will have over 1 day of ADV to sell. The actual impact could be higher as cash and carry baskets are rebalanced and active managers reposition their portfolios to no deviate too far from their benchmark.The inclusions have outperformed the deletions by 15% over the last month and while there could be a pop in the returns over the next few sessions, we recommend gradually exiting existing positions and re-entering prior to implementation on a selloff in the trade.

CSI300 Index Rebalance: 25 Changes as Long/Short Trade Does Well

China

Guangzhou Kingmed Diagnostics Group Co., Ltd. operates as a medical laboratory. The Company provides clinical testing, pathology diagnosis outsourcing, and other services. Guangzhou Kingmed Diagnostics Group provides services to various medical institutions including hospitals, maternal, child health centers, health centers, and other places.

Guangzhou Kingmed Diagnostics (603882 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Guangzhou Kingmed Diagnostics (603882 CH)

Pre-IPO ADICON Holdings Ltd - Insights on Industry, Business and Concerns

This insight mainly analyzed ADICON in terms of the ICL industry characteristics in China, the business model of ADICON, the comparison with peers,...

Xinyao (Criss) Wang

Kindstar Globalgene IPO: Valuation Insights

At the mid-point of the IPO price range, the total net proceeds are HK$1,931.1 million ($250 million). Overall, we would participate in the IPO due...

Arun George

Kindstar Globalgene (康圣环球) IPO: Fairly Valued for a Questionable Moat

We think Kindstar is fairly valued for its fundamentals. Its moat is not as wide as many investors would think. Therefore we would avoid the deal.

Ke Yan, CFA, FRM

Kindstar Globalgene IPO Initiation: Testing, Testing

Kindstar is set to launch an IPO to raise around $300 m. It has successfully overcome the COVID-19 pandemic. In combination, with operating...

Arun George

CSI300 Index Rebalance: 25 Changes as Long/Short Trade Does Well

There are 25 changes to the CSI300 Index that will be implemented at the close on 11 June. One-way turnover is 3.67% and the adds have outperformed...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)